Medically reviewed by Dr. Jeremy M. Burnham, MD, Orthopedic Surgery
“GLP-1 peptide” is not one decision. It is three. A person is choosing between an FDA-approved prescription product, a compounded preparation made by a licensed pharmacy, and a vial sold as a research chemical. Only the first two sit inside medical care at all. Placing a product in the right category settles most of what follows.
Why the word peptide settles nothing
A peptide is a short chain of amino acids. That is a statement about chemistry and nothing more. Insulin is a peptide. Semaglutide is a peptide. So are various compounds shipped in unmarked vials by websites that ask no medical questions before taking payment. The term describes molecular architecture, not approval status, not manufacturing standards, and not whether anyone has studied a human being taking it.
Sellers of unapproved material lean on that ambiguity. A listing can say “research-grade GLP-1 peptide” and stay chemically defensible while implying something it has no basis for, which is that the contents behave like a prescription medicine. FDA’s review of peptide bulk substances explains why the inference collapses. Peptides carry immunogenicity risk that varies by route of administration, they accumulate peptide-related impurities, and characterizing the active ingredient is hard enough that the agency has named it a recurring obstacle across nomination reviews of compounds such as CJC-1295, ipamorelin acetate, and GHRP-2.
Three categories that share a vocabulary
Nearly every argument about GLP-1 products is really an argument about which of these three columns someone is standing in. The categories differ on who reviewed the product, who is accountable if something goes wrong, and what evidence exists about the exact material in the container.
| Category | Representative products | Regulatory position | How it reaches a person |
|---|---|---|---|
| FDA-approved prescription drug | Ozempic and Wegovy (semaglutide), Rybelsus, Mounjaro and Zepbound (tirzepatide), Victoza and Saxenda (liraglutide), Foundayo (orforglipron) | Reviewed for safety, effectiveness, and quality before marketing; carries an FDA-approved label | Prescription filled at a licensed pharmacy |
| Pharmacy-compounded preparation | Compounded semaglutide and tirzepatide | Not FDA-approved; not reviewed for safety, effectiveness, or quality before marketing | Prescription written by a clinician, prepared by a compounding pharmacy or outsourcing facility |
| Material sold as a research chemical | Vials marketed under molecule names with no prescriber involved | Outside the prescription system entirely; contents, purity, and identity unverified by any regulator | Direct online sale, often shipped without temperature control |
One nuance is worth holding onto, because it cuts against the category label itself. Foundayo, the oral orforglipron product approved for weight reduction and long-term weight maintenance in adults with obesity or overweight plus a weight-related condition, is a GLP-1 receptor agonist that is not a peptide. It is a small molecule, which is why it can be swallowed as a tablet rather than engineered around peptide degradation.
Where price pushes the decision
Cost is the pressure point that moves people between columns. Brand list prices for weight-labeled products run into four figures a month before insurance, and Medicare Part D historically excluded drugs used for weight loss from required coverage, with commercial plans applying their own step edits and exclusions. That gap created a large cash-pay market operating alongside the pharmacy benefit.
Several named services now publish flat monthly cash figures rather than routing everything through insurance. Ro, Hims and Hers, LifeMD, and physician-supervised programs such as FormBlends all sit in that band, and each requires a clinician review before anything ships. Comparing one of those monthly figures against a brand list price is not a like-for-like comparison, because a compounded preparation and an approved product do not hold the same regulatory status even when the molecule name matches.
What a prescriber is actually deciding
Approved labels do not simply say “for weight loss.” Each one names a population, a set of contraindications, and a monitoring expectation. The 2025 Canadian clinical practice guideline update on obesity pharmacotherapy frames drug selection around comorbid conditions and long-term continuation rather than around headline weight figures, which is closer to how a clinical decision actually runs than any product page suggests.
That is also the reason a self-directed purchase removes more than a signature. It removes the review of interacting conditions, the escalation plan, the record that lets someone correlate a symptom with a dose change, and the person who answers when a symptom appears at week six.
Comparing named services gets easier once each one states how it works. Some route people toward a manufacturer’s approved product through channels like LillyDirect and NovoCare, while others such as Henry Meds, Ro, and HealthRX build their own intake and describe how their peptide therapy options are prescribed and which pharmacy fills them. Reading those disclosures side by side tells a person more about accountability than any single monthly price does, and it keeps the choice anchored to who stands behind the medicine rather than to the molecule name alone.
Signals that a seller sits outside medical supply
FDA publishes a specific list of telehealth warning signs for this category. It is short and unusually concrete:
- Claims that a compounded drug is the same as an FDA-approved drug
- Pricing far below anything else in the market
- No screening and no prescription from a licensed clinician before medicine is provided
- No clinician available after delivery to answer questions
- Label spelling errors, incorrect pharmacy addresses, or a pharmacy name that appears fabricated
- Injectable product arriving warm or with inadequate ice packs
The agency has also documented fraudulent compounded semaglutide and tirzepatide carrying false label information, including labels naming pharmacies that do not exist or that did not compound the product. That is a supply-chain problem, not a chemistry problem, and no amount of reading about receptor pharmacology protects against it.
Frequently asked questions
Is a compounded GLP-1 a generic version of the brand?
No. A generic is an approved product shown to be equivalent to a reference drug through an FDA application. A compounded preparation goes through no such review. FDA states plainly that compounded drugs are not FDA-approved and are not assessed for safety, effectiveness, or quality before they are marketed.
Does research-use labeling mean the contents are the same molecule?
It means nothing verifiable. Nobody has confirmed identity, potency, sterility, or impurity profile against a standard. FDA has separately noted that retatrutide and cagrilintide cannot lawfully be used in compounding and are not components of any approved drug, and has warned distributors and telehealth sellers marketing them.
Are all approved GLP-1 medicines peptides?
No, and that exception matters for the vocabulary. Semaglutide, tirzepatide, and liraglutide are peptides. Orforglipron, sold as Foundayo, is an oral small-molecule GLP-1 receptor agonist. The class is defined by which receptor a drug activates, not by whether the molecule happens to be a chain of amino acids.
Does a salt form count as the same active ingredient?
FDA says it does not. The agency has identified semaglutide sodium and semaglutide acetate being sold by some compounders and describes them as different active ingredients from the one in the approved drugs, with no information showing the salts share the same chemical and pharmacologic properties.
If insurance covers a brand product, does anything else matter?
The decision gets much simpler. An approved product with a published label, an established supply chain, and a covered copay removes most of the tradeoffs that make the other two categories worth discussing at all. Coverage terms for weight indications still vary widely between plans.
Sources
- FDA, FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss: https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- FDA, Compounding and the FDA: Questions and Answers: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
- FDA, Certain Bulk Drug Substances for Use in Compounding May Present Significant Safety Risks: https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- DailyMed, Foundayo (orforglipron) prescribing information: https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=FOUNDAYO
- DailyMed, Wegovy prescribing information: https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=WEGOVY
- DailyMed, Zepbound prescribing information: https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=ZEPBOUND
- Pharmacotherapy for obesity management in adults: 2025 clinical practice guideline update. PubMed: https://pubmed.ncbi.nlm.nih.gov/40789597/
- Navigating compounded semaglutide: what health care providers need to know. PubMed: https://pubmed.ncbi.nlm.nih.gov/40966636/
- CMS, Prescription Drug Coverage: https://www.cms.gov/medicare/coverage/prescription-drug-coverage
